Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 13 | 494 | 40% |
| 2020 | 11 | 491 | 43% |
| 2021 | 13 |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 98% of the cases CMS names in North Carolina; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 133 | 8,308−3%/yr | −3%/yr | 9.01.3× | 45% | 8,490 in 2030+0.4%/yr |
| Tumor ablation |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
| ≈ 1,260 |
| – |
| 2026 est. | ≈ 1,370 | – |
| 480 |
| 48% |
| 2022 | 8 | 653 | 52% |
| 2023 | 9 | 756 | 56% |
| 2024 | 11 | 795 | 59% |
| 2025 from claims | – | 1,260 1,019–1,480 | 61% |
| 2026 forecast | – | 1,374 1,076–1,725 | 62% |
| 2027 forecast | – | 1,491 1,106–1,971 | 62% |
| 2028 forecast | – | 1,617 1,145–2,232 | 63% |
| 2029 forecast | – | 1,753 1,192–2,514 | 64% |
| 2030 forecast | – | 1,899 1,244–2,819 | 65% |
In 2025, 3% inpatient hospital, 34% hospital outpatient, 63% office. The share outside the hospital has moved +63 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~1,400 | ~33 | ~390 | ~950 |
| 2027 · ~1,500 | ~34 | ~380 | ~1,100 |
| 2028 · ~1,600 | ~35 | ~390 | ~1,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 74% (63% in 2025), hospital outpatient about 24% (34% in 2025).
| +2.9%/yr |
| 0.6 |
| 63% |
| 3,140 in 2030+17%/yr |
| Virginia | 12 | 902+21%/yr | +21%/yr | 0.9 | 55% | 2,310 in 2030+17%/yr |
| Maryland | 12 | 701+17%/yr | +17%/yr | 0.8 | 80% | 1,270 in 2030+10%/yr |
| Tennessee | 13 | 482+8.1%/yr | +8.1%/yr | 0.7 | 71% | 1,670 in 2030+23%/yr |
| Georgia | 5 | 259−8.1%/yr | −8.1%/yr | 0.3 | 64% | 920 in 2030+23%/yr |
| Kentucky | 1 | 248+17%/yr | +17%/yr | 0.5 | 79% | 1,090 in 2030+28%/yr |
| South Carolina | 7 | 207−3.3%/yr | −3.3%/yr | 0.3 | 46% | 820 in 2030+26%/yr |
| Alabama | 5 | 198+0.2%/yr | +0.2%/yr | 0.5 | 68% | 810 in 2030+26%/yr |
| Mississippi | 6 | 194+19%/yr | +19%/yr | 0.5 | 36% | 380 in 2030+12%/yr |
| Oklahoma | 2 | 185+1.4%/yr | +1.4%/yr | 0.4 | 22% | 180 in 2030−0.6%/yr |
| Louisiana | 3 | 167−2.6%/yr | −2.6%/yr | 0.4 | 37% | 260 in 2030+7.6%/yr |
| Arkansas | 3 | 165−1.3%/yr | −1.3%/yr | 0.4 | 73% | 740 in 2030+29%/yr |
| District of Columbia | 3 | 100−4.1%/yr | −4.1%/yr | 1.6 | 87% | 160 in 2030+7.9%/yr |
| 3 |
| 334−1.9%/yr |
| −1.9%/yr |
| 0.31.1× |
| 0% |
| 320 in 2030−0.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 37243 (vasc embolize/occlude organ), commercial plans pay North Carolina’s hospitals a median of $11K, from $8,496 at the lowest to $11K at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.
Exact Sciences leads with 38% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 16 companies reported engagement with North Carolina’s surgeons worth $242K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.